ArticlePrecision radiation oncology2025
A safety study of ultra-high dose rate FLASH radiotherapy in the treatment of superficial skin tumors: study protocol of a phase I trial (ChiCTR2400080935).
Article in Precision radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Expert consensus on clinical trial design guidelines for FLASH radiotherapy.Precision radiation oncology · 2026Article
- One-year follow-up after fractionated ultra-high-dose-rate FLASH radiotherapy in patient with extramammary Paget disease of the scrotum.Precision radiation oncology · 2026Article
- FLASH radiotherapy enables dose escalation resulting in improved survival in an orthotopic muscle-invasive bladder cancer mouse model.The British journal of radiology · 2026Article
- Microenvironmental remodeling in FLASH radiotherapy.Frontiers in cell and developmental biology · 2026Review
- The symbiotic axis between the acidic tumor microenvironment and cancer stem cells: a driver of malignancy and therapeutic resistance.Frontiers in oncology · 2026Review
- Ultra-high-dose-rate pulsed irradiation and the conditional FLASH effect: dosimetry, multiscale biology, and clinical translation.Frontiers in oncology · 2026Review
- An optimal graph convolutional vision neural network with explainable feature optimization for improved skin cancer detection.BMC medical imaging · 2025Article
- A safety study of ultra-high dose rate FLASH radiotherapy in the treatment of superficial skin tumors: study protocol of a phase I trial (ChiCTR2400080935).Precision radiation oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Ultra-high dose rate FLASH radiotherapy (FLASH-RT) is emerging as a novel technique to improve the normal tissue tolerance by delivering ultra-high dose rate radiation several orders of magnitude higher than convention radiotherapy. It has been shown in preclinical studies to cause less injury to surrounding normal tissues during radiation treatment, while still maintaining local tumor control. The purpose of this protocol is to evaluate the safety of fractionated FLASH-RT in skin cancer. Method: Patients with superficial skin tumors will be enrolled. The eligible patients will undergo electron FLASH-RT (24-40 Gy/3-5 fractions) to the tumor volume. The primary outcome is to evaluate the safety of FLASH-RT by collecting the acute (< 90 days) skin toxicity adverse events of radiation according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Secondary objectives include late (> 90 days) skin toxicity after FLASH-RT according to CTCAE version 5.0 and treatment response. Discussion: If the results show that delivering FLASH-RT is safe and feasible for skin tumors, further investigation will be conduct to evaluate efficacy of FLASH-RT in a phase II trial. Trial Registration number: ChiCTR2400080935. https://www.chictr.org.cn/showproj.html?proj=220336.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.